ImCare Biotech recently published the results from its clinical study in the peer-reviewed journal Clinical and Translational Gastroenterology. The study, which was a prospective, double-blinded study, assessed Seravue’s ability to differentiate between patients with Hepatocellular Carcinoma (HCC), and benign liver conditions such as cirrhosis and chronic Hepatitis B and C. For any-stage HCC patients, Seravue demonstrated […]
ImCare Biotech Team
(47101)
